Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
$0.34
$0.37
$0.80
$1.82
$3.09M2.034,760 shsN/A
International Stem Cell Co. stock logo
ISCO
International Stem Cell
$0.07
$0.09
$0.05
$0.17
N/A0.521,261 shsN/A
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
$0.48
$0.31
$10.10
$6.88M4.16713,628 shsN/A
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
$2.02
+2.5%
$13.23
$4.50
$27.32
$2.90M2.0778,851 shs67,382 shs
XTLB
XTL Biopharmaceuticals
$2.40
-6.3%
$3.99
$1.73
$6.69
$13.08M1.21112,627 shs6,198 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
0.00%-12.66%-5.36%-13.49%-38.61%
International Stem Cell Co. stock logo
ISCO
International Stem Cell
+6.21%-8.71%+6.38%-19.85%-55.17%
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
0.00%0.00%0.00%0.00%0.00%
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
0.00%+25.48%-7.08%+8.24%-12.05%
XTLB
XTL Biopharmaceuticals
-6.25%-1.64%-21.82%+172.48%+100.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
International Stem Cell Co. stock logo
ISCO
International Stem Cell
N/AN/AN/AN/AN/AN/AN/AN/A
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
XTLB
XTL Biopharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/AN/AN/AN/A
International Stem Cell Co. stock logo
ISCO
International Stem Cell
N/AN/AN/AN/A
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
N/AN/AN/AN/A
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/AN/AN/AN/A
XTLB
XTL Biopharmaceuticals
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/AN/AN/AN/A($0.07) per shareN/A
International Stem Cell Co. stock logo
ISCO
International Stem Cell
$7.79MN/AN/AN/A($0.57) per shareN/A
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
$96.43M0.00N/AN/A$16.96 per share0.00
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/AN/AN/AN/A$13.13 per shareN/A
XTLB
XTL Biopharmaceuticals
N/AN/AN/AN/A$0.73 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
-$1.11M-$0.40N/AN/AN/AN/A-288.85%N/A
International Stem Cell Co. stock logo
ISCO
International Stem Cell
-$130K-$0.03N/AN/A-2.68%-2.80%-3.77%N/A
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
-$157.19M-$17.72N/AN/AN/A-393.39%-101.29%-28.68%N/A
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
-$16.01M-$21.58N/AN/AN/AN/A-133.49%-30.52%N/A
XTLB
XTL Biopharmaceuticals
-$1.35M-$0.42N/AN/AN/A-73.05%-68.83%5/21/2024 (Estimated)

Latest MLNT, ICOTF, ISCO, XTLB, and NVUS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
International Stem Cell Co. stock logo
ISCO
International Stem Cell
N/A-$0.04-$0.04-$0.04N/A$1.89 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/AN/AN/AN/AN/A
International Stem Cell Co. stock logo
ISCO
International Stem Cell
N/AN/AN/AN/AN/A
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
N/AN/AN/AN/AN/A
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/AN/AN/AN/AN/A
XTLB
XTL Biopharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/A
0.72
0.72
International Stem Cell Co. stock logo
ISCO
International Stem Cell
N/A
0.73
0.47
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
1.11
1.03
0.72
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/A
18.78
18.78
XTLB
XTL Biopharmaceuticals
N/A
14.09
N/A

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/A9.05 millionN/ANot Optionable
International Stem Cell Co. stock logo
ISCO
International Stem Cell
29N/AN/ANot Optionable
Melinta Therapeutics Inc stock logo
MLNT
Melinta Therapeutics
29013.75 millionN/AOptionable
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
71.44 millionN/ANot Optionable
XTLB
XTL Biopharmaceuticals
N/A5.45 million3.87 millionNot Optionable

MLNT, ICOTF, ISCO, XTLB, and NVUS Headlines

SourceHeadline
XTL Biopharmaceuticals Ltd. ADRXTL Biopharmaceuticals Ltd. ADR
wsj.com - April 26 at 6:16 AM
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.03%U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.03%
msn.com - March 20 at 8:50 PM
US Stocks Edge Lower Ahead Of Feds Decision; General Mills Earnings Top ViewsUS Stocks Edge Lower Ahead Of Fed's Decision; General Mills Earnings Top Views
msn.com - March 20 at 3:48 PM
Dow Surges 350 Points; Fed Holds Rates SteadyDow Surges 350 Points; Fed Holds Rates Steady
markets.businessinsider.com - March 20 at 3:48 PM
Crude Oil Surges 2%; Signet Jewelers Shares Spike HigherCrude Oil Surges 2%; Signet Jewelers Shares Spike Higher
markets.businessinsider.com - March 20 at 3:48 PM
XTL To Aquire The Social ProxyXTL To Aquire The Social Proxy
globenewswire.com - March 20 at 10:15 AM
XTL Biopharmaceuticals Ltd ADR (XTLB)XTL Biopharmaceuticals Ltd ADR (XTLB)
investing.com - February 17 at 10:28 AM
Call for ProposalsCall for Proposals
raps.org - February 11 at 2:00 PM
XTL Biopharmaceuticals Ltd (H2K2.MU)XTL Biopharmaceuticals Ltd (H2K2.MU)
finance.yahoo.com - October 23 at 11:13 PM
XTL Biopharmaceuticals Ltd.: XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyXTL Biopharmaceuticals Ltd.: XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
finanznachrichten.de - October 23 at 12:16 AM
XTL Biopharmaceuticals Ltd.: XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in IsraelXTL Biopharmaceuticals Ltd.: XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel
finanznachrichten.de - October 21 at 8:22 AM
XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in IsraelXTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel
finance.yahoo.com - October 20 at 7:35 PM
XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyXTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
finance.yahoo.com - October 20 at 7:35 PM
Is X T L Biopharmaceuticals Ltd (ADR) (XTLB) Stock a Good Investment?Is X T L Biopharmaceuticals Ltd (ADR) (XTLB) Stock a Good Investment?
aaii.com - March 30 at 3:19 PM
XTLB XTL Biopharmaceuticals Ltd.XTLB XTL Biopharmaceuticals Ltd.
seekingalpha.com - October 1 at 8:47 PM
X T L Biopharmaceuticals LtdX T L Biopharmaceuticals Ltd
reuters.com - August 8 at 10:32 PM
LIFE, TBLT and XTLB among pre market gainersLIFE, TBLT and XTLB among pre market gainers
seekingalpha.com - July 23 at 7:53 AM
XTL Biopharmaceuticals Year to Date Total Returns (Daily)XTL Biopharmaceuticals Year to Date Total Returns (Daily)
ycharts.com - December 18 at 11:24 PM
XTL Biopharmaceuticals Dividend Per Share (TTM)XTL Biopharmaceuticals Dividend Per Share (TTM)
ycharts.com - December 18 at 1:03 AM
XTL Biopharmaceuticals Ltd. (XTLB)XTL Biopharmaceuticals Ltd. (XTLB)
uk.finance.yahoo.com - December 15 at 10:18 AM
X.T.L. Biopharmaceuticals Ltd. - ADRX.T.L. Biopharmaceuticals Ltd. - ADR
money.usnews.com - September 26 at 12:03 AM
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) Up 1.8% This Year: What Should You Expect Next?XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) Up 1.8% This Year: What Should You Expect Next?
stocksregister.com - August 23 at 4:44 PM
Is XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) Expensive At $4.67? Here’s How To Know.Is XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) Expensive At $4.67? Here’s How To Know.
marketingsentinel.com - August 20 at 5:09 PM
How Is XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) Expected To Fare In The Coming Months?How Is XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) Expected To Fare In The Coming Months?
marketingsentinel.com - July 26 at 9:30 AM

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

iCo Therapeutics logo

iCo Therapeutics

OTCMKTS:ICOTF
Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.
International Stem Cell logo

International Stem Cell

OTCMKTS:ISCO
International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC- hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson's disease, as well as for treating stroke and traumatic brain injury. The company also offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, ProPlus Eye Firming Complex, ProPlus Neck Firming Complex, ProPlus Advanced Aqueous Treatment, ProPlus Collagen Booster, ProPlus Elastin Booster, and ProPlus Brightening Toner. In addition, it provides human cell culture products comprising human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. International Stem Cell Corporation was founded in 2001 and is headquartered in San Diego, California.
Melinta Therapeutics logo

Melinta Therapeutics

NASDAQ:MLNT
Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is headquartered in New Haven, Connecticut.
Novus Therapeutics logo

Novus Therapeutics

NASDAQ:NVUS
Novus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.

XTL Biopharmaceuticals

NASDAQ:XTLB
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.